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Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare
autosomal recessive disease, caused by mutations of a single gene named Autoimmune
regulator gene (AIRE) which results in a failure of T-cell tolerance. Central tolerance takes
place within the thymus and represents the mechanism by which potentially auto-reactive
T-cells are eliminated through the negative selection process. The expression of tissue-
specific antigens (TSAs) by medullary thymic epithelial cells (mTECs) in the thymus is a
key process in the central tolerance and is driven by the protein encoded by AIRE gene,
the transcription factor autoimmune regulator (AIRE). A failure in this process caused by
AIRE mutations is thought to be responsible of the systemic autoimmune reactions of
APECED. APECED is characterized by several autoimmune endocrine and non-endocrine
manifestations and the phenotype is often complex. Although APECED is the paradigm of
a monogenic autoimmune disorder, it is characterized by a wide variability of the clinical
expression even between siblings with the same genotype, thus implying that additional
mechanisms, other than the failure of Aire function, are involved in the pathogenesis of
the disease. Unraveling open issues of the molecular basis of APECED, will help improve
diagnosis, management, and therapeutical strategies of this complex disease.
Keywords: autoimmune polyglandular syndrome type 1, APECED, autoimmune regulator gene, phenotypic
variability, tolerance
INTRODUCTION
Autoimmune Polyglandular Syndrome Type 1 (APS-1), also
called Autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED), is a rare autosomal recessive disease caused
by mutations of the autoimmune regulator gene (AIRE). Immuno-
logically, APECED is characterized by destruction of the target
organs by a cellular- and/or antibody-mediated attack (1). In the
past decade, much interest has been focused on the pathogene-
sis of this syndrome. Indeed, APECED represents a paradigm of
genetically determined systemic autoimmunity. However, the great
variability that characterizes APECED, irrespectively of the AIRE
genotype, implies that several factors are involved in the disease
phenotypic expression.
In this review, we will focus on the complex pathogenesis of
APECED and on the potential interfering factors involved in the
clinical expression of the disease.
THE BASIS OF THE IMMUNOLOGICAL TOLERANCE
Tolerance represents a state of immunologic non-responsiveness
in the presence of a particular antigen. In this context, T-cell
tolerance is crucial for the creation of a proper T-cell reper-
toire, able to respond to a huge number of foreign antigens, but
preventing autoimmune reactions. Imposition and regulation of
self-tolerance within the T-cell repertoire is exerted at two levels:
(1) central tolerance (development and selection of T-cells in the
thymus) and (2) peripheral tolerance (deletion, anergy of mature
T-cells in lymphoid and non-lymphoid organs) (2).
T-cell central tolerance, established within the thymus, mostly
relies on two main mechanisms: negative selection, also referred
to as clonal deletion of maturing thymocytes and positive selec-
tion of maturing T-cells able to bind to a surface major histo-
compatibility complex (MHC) molecule with mild threshold of
reactivity (Figure 1). The thymus provides the necessary envi-
ronment for thymopoiesis and establishment and maintenance
of self-tolerance (3–5). Thymus contains thymic epithelial cells
(TECs) that form a complex three-dimensional network orga-
nized in cortical and medullary compartments (6). On entering the
thymus, immature thymocytes promote the differentiation of pre-
cursor thymic epithelial cells (pTECs) into cortical TECs (cTECs)
and medullary TECs (mTECs), playing an important role in the
formation of the thymic microenvironment (7–9). During post-
natal life, hematopoietic progenitors enter the thymus from the
bloodstream (10) and cells committed to the T lineage undergo
division, mostly within the double-negative (DN) stage of the T-
cell development. The first checkpoint is the rearrangement of
T-cell receptor (TCR) β and α locus. Expression of αβ TCR het-
erodimers on the cell surface allows DN thymocytes to progress
to the double-positive (DP) CD4+CD8+ stage. At DP stage, the
TCR affinity for self-peptide-MHC on mTECs within the thymus
determines thymocyte’s fate. mTECs express a wide array of tissue-
specific antigens (TSAs) in the context of MHC class II molecules;
these TSAs include self-proteins derived from different organs in
the body. DP thymocytes expressing TCRs that do not bind self-
peptide-MHC complexes are programed to undergo “death by
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FIGURE 1 | Positive and negative selection of immature thymocytes within thymus.
neglect” or apoptosis. Only about 5% of DP has a low affinity for
self-peptide-MHC complexes and differentiate to CD4+CD8− or
CD4−CD8+ single positive (SP) lineage (positive selection) (11–
13). DP thymocytes with high-affinity TCR for MHC complexes
represent a potential reservoir of auto-reactive lymphocytes and
“clonal deletion” (negative selection) is the main mechanism in
the thymus to preserve self-tolerance (14, 15). Compelling evi-
dence indicates that an altered promiscuous thymic expression of
TSAs leads to autoimmunity. In the autoimmune attack, T helper
cells (Th) escaped to self-tolerance, produce pro-inflammatory
cytokines able to begin inflammation and activate auto-reactive
B-cells, resulting in autoantibodies production, which lead to tis-
sue inflammation and damage (1). Some of the thymocytes that
recognize self-peptide-MHC complexes with high-affinity express
Foxp3 and through “clonal diversion” mature as regulatory T-
cells (Tregs), which are able to suppress auto-reactive T-cells in
the periphery (16–18). The central tolerance is not able alone to
completely remove mature T-cells with self-antigens specificity,
therefore additional mechanisms in the periphery are also needed
to maintain immunological tolerance.
The peripheral tolerance recognizes as possible mechanisms the
induction of functional anergy, deletion of auto-reactive clones,
and the suppressive action of T-regulatory cells (Tregs). Anergy
is a state of long-term hyporesponsiveness with inactivation of
self-reactive T-cells in the presence of a TCR signal but in the
absence of a second costimulatory signal, necessary to T-cell acti-
vation. Deletion of self-reactive lymphocytes is achieved in both
the thymus and the periphery by apoptosis through interaction of
Fas/FasL. The function of Tregs (Foxp3-expressing CD4 T-cells)
is to suppress immune responses through numerous mechanisms
including the production of anti-inflammatory cytokines, direct
cell–cell contact, and by modulating the activation state and func-
tion of antigen-presenting cell (APC) (19). An additional mech-
anism involved in controlling reactivity to self in the periphery is
NK cell activity.
AIRE AND THE MAINTENANCE OF IMMUNOLOGICAL
TOLERANCE
Autoimmune regulator gene encodes for a transcription factor
(Aire) involved in the maintenance of tolerance. In humans, the
AIRE gene maps to chromosome 21q22.3 (20, 21). It consists of 14
exons spanning 11.9 kb of genomic DNA (22) and encodes a 545
amino acid protein with a molecular weight of 58 kDa that works as
a “non-classical” transcriptional factor in immune-related organs.
The highest level of AIRE expression has been detected within the
thymus (23) in mTECs, followed by thymic dendritic cells (DCs).
In addition to the thymus, low level of Aire seems to be expressed
in secondary lymphoid organs, such as lymph nodes, fetal liver,
and spleen (24, 25). The Aire protein, mostly localized in the cell
nucleus, is composed by specific domains including the amino-
terminal HSR domain, the nuclear localization signal (NLS), the
Sp100, AIRE1, nucP41/75, DEAF 1 (SAND) domain, two plant
homeodomain (PHD) type zinc fingers, and four LXXLL motifs
(26) (Figure 2). The HSR region has been shown to be responsible
for the dimerization of the polypeptides belonging to the Sp100
protein family (27). The SAND domain is important for AIRE
transactivation capacity and subcellular localization. The PHD
zinc fingers are often found in proteins involved in the regulation
of transcription (28). The LXXLL motifs are found on coactiva-
tors nuclear receptors and proline-rich regions (PRR) and are also
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FIGURE 2 | AIRE gene (top) and corresponding protein (bottom) with functional domains. The Aire protein is composed by nuclear localization sequences
(NLS), two planthomeodomain (PHD) zinc fingers, a caspase recruitment domain (CARD)/homogeneously staining region (HSR), a SAND domain, and a
proline-rich region (PRR).
associated to transcription regulation (29). Although the precise
molecular mechanism is still unclear, Aire seems to regulate the
transcription process acting as a coactivator in a large transcrip-
tional complex (30), and interacting with a large set of partners,
divided into four main classes based on their function: nuclear
transport, chromatin binding/structure, transcription, and pre-
mRNA processing factors (31). The first protein reported to bind to
AIRE was CREB-binding protein (CBP) (32). Its interaction with
AIRE may lead to promotion of gene transcription through histone
acetylation and the recruitment of chromatin-transcription fac-
tors (33). Other AIRE partners have been identified, such as DNA
protein kinase (DNA-PK), SP-RING domain protein inhibitor of
activated STAT1 (PIAS1), positive transcription elongation factor
b (P-TEFb) (34–36). Moreover, it has been proposed a possible
epigenetic control of the AIRE target genes since AIRE’s PHD1
finger domain appears to be able to bind histone three molecules
with unmethylated lysine at position 4, generally associated with
repressed genes (37). Overall, it is possible that Aire mediates the
expression of TSA in mTECs through its co-transcriptional part-
ners (38). The intriguing question is how the AIRE gene alone can
influence the transcription of such a large number of TSA genes.
Indeed, two models have been suggested to explain the action of
Aire: transcription model and maturation model. In the transcrip-
tion model, TSAs are considered to be the direct target genes of
Aire’s transcriptional activity and the lack of Aire protein within
the cell would result in the defective TSA gene expression, while the
maturation program of mTECs would be in principle unaffected.
The maturation model suggests that Aire may affect the thymic
microenvironment more globally than through simple control of
TSA expression levels. Consequently, in keeping with the latest
model the regulation of TSA gene expression might not be the
major defect of Aire-deficient mTECs responsible for impaired
negative selection (39).
Although the exact role of AIRE in controlling T-cell tolerance
is still largely unclear, several mechanisms have been suggested.
Functional alterations of AIRE may affect processing and/or
presentation of self-antigens within the mTECs (40). The process
of thymocyte maturation (41), the attraction of mature thymo-
cytes to their final location for a proper negative selection (40,
42), the control of cross-presentation through alteration of the
relationship between APCs and mTECs (43) may also represent
potential mechanisms by which AIRE alterations may lead to func-
tional abnormalities of the central tolerance. The alteration in the
balance between negative selection and regulatory T-cell produc-
tion (44) may also be implicated in the pathogenesis. In addition,
Aire may also play a role in the proper differentiation of the thymic
medullary epithelium, in the induction of apoptosis in end-stage
terminally differentiated mTECs (39) as well as in mTECs’ dif-
ferentiation program. In particular, evidence suggests that lack of
Aire in mTECs results in an arrest of the differentiation program,
with the cells remaining at the premature stage just before terminal
differentiation (45, 46).
THE CLINICAL COUNTERPART OF AIRE MUTATION: APECED
GENETIC BACKGROUND
Mutations in AIRE gene result in development of APECED, which
represents the paradigm of a genetically determined failure of
central tolerance leading to autoimmunity (46). APECED is a
rare autoimmune syndrome, but it has been reported worldwide
showing a relatively higher prevalence in genetically isolated pop-
ulations such as Iranian Jews (1:9,000) (47), Finns (1:25,000)
(48, 49), and Sardinians (1:14,400) (50). It is also quite fre-
quent in Norway (1:90,000) (51) and in some regions of Italy
(52–55). The most frequent model of inheritance is autosomal
recessive, even though a dominant pattern has also been spo-
radically reported (56). So far, over 70 different mutations of
AIRE have been documented (2). Due to the molecular organi-
zation and the complexity of intermolecular connection of Aire, it
would be expected that different mutation in the molecule might
imply different functional abnormalities, thus being associated
with a variable phenotypic expression. Single nucleotide substi-
tutions, small insertions, deletions, and mutations affecting splice
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consensus sequences have been identified along the entire coding
region, and include either nonsense or frameshift mutations that
result in truncated polypeptides, or missense mutations that result
in single amino acid-changing (27). Most of these AIRE mutations
lead to a change in its subcellular location altering the distrib-
ution of the protein between the nucleus and cytoplasm (27).
Mutations of the predicted surface area of the HSR domain cause
the protein accumulation in the nucleus blocking its cytoplas-
mic localization probably enhancing nuclear import or inhibiting
nuclear export (57). Mutations of the SAND domain disturb the
distribution of Aire between the nucleus and cytoplasm suggesting
a role for the SAND domain in nuclear transport mechanisms (57).
Moreover, since the six helix CARD domain is involved in homod-
imerization, missense mutations in this region often affect Aire
multimerization or localization to nuclear bodies (58) while most
of the missense mutations in PHD domains alter the zinc-finger
fold and decrease Aire’s transcriptional activation capacity (38).
Some different mutations have been found to be peculiar to
certain populations. R257X is the most common mutation among
Finnish and other European patients (59–61). R257X is a nonsense
mutation, which most probably results in a carboxy-terminally
truncated, non-functional Aire protein leading to alterated sub-
cellular localization and inhibition of the transactivation function
and complex formation of Aire (27). The 1094–1106 del113 (or
967–979 del-13 bp) is the most common mutation in British (62),
Irish (63), North American (64, 65), and Norwegian patients (51)
leading to the truncation and loss of function of Aire. Y85C is the
only missense mutation found among Iranian Jews (57). In Italy,
typical mutations of AIRE have been detected in Sardinia (R139X
on exon 3) (50, 54), where this nonsense mutation leads to a total
absence of Aire and seems to be associated with a more severe
phenotype. In Apulia, the missense mutation W78R on exon 2,
and the nonsense mutation Q358X on exon 9 have been found.
The mutation Q358X lies in the PRR resulting in a truncated pro-
tein which lacks the second PHD finger and thereby is most likely
non-functional protein (53). In Sicily, the most frequent mutation
is R203X on exon 5, and two novel mutations, S107C and Q108fs
on exon 3, have been detected. The mutation S107C is a mis-
sense mutation, whilst Q108fs is a small deletion, both affecting
the HSR domain of Aire protein and it is likely that the Aire pro-
tein loses its homodimerization properties (66, 67). In Venetian
patients, the most frequent mutations are R257X on exon 6 and
979 del-13 bp on exon 8, that are analogous to those detected in
Finnish and Anglo-saxon patients but different from Italian ones
(55). No typical mutations have been identified neither in Calabria
nor in Campania (52, 68) even though patients from Campania
show a high frequency of mutations in the exon/intron 1 junction.
Compared to other mutations, the R257X results in a total loss of
function, whereas the less dramatic truncations of the AIRE pro-
tein and many missense mutations, especially the predicted surface
mutations of the HSR domain and the mutations in the leucine
zipper domain, seem to exert less severe effects on the function of
the Aire protein (27). Therefore, despite considerable variations in
the APECED genotype, correlations with specific phenotypic fea-
tures are far from being well elucidated. Only in patients affected
with Candida infection, a correlation has been proved. In fact, can-
didiasis was significantly less prevalent in patients homozygous for
967–979del-13bp than in patients carrying the R257X or R139X,
suggesting that AIRE truncation upstream the SAND domain
promotes the susceptibility to this infection (69).
DIAGNOSIS OF APECED
The onset of APECED usually occurs during childhood. The clin-
ical diagnosis is based on the presence of two of the three classical
components: chronic mucocutaneous candidiasis (CMC), chronic
hypoparathyroidism (CH), and Addison’s disease (AD). The pres-
ence of only one of these features is sufficient for the diagnosis,
when a sibling is affected. Molecular analysis of AIRE may help
to confirm the clinical diagnosis, in particular in those cases
with an atypical presentation (70, 71). Neutralizing autoantibodies
against IFN-ω and IFN-α may represent a precocious biomarker
detectable in the majority of patients and, thus they have been
recently included in the diagnostic criteria of APECED (72).
CLINICAL EXPRESSION, AUTOANTIBODIES PROFILE, AND
SUSCEPTIBILITY FACTORS
APECED is characterized by a highly variable pattern of
destructive autoimmune reaction, mainly mediated by specific
autoantibodies toward different endocrine and non-endocrine
organs. Virtually, all tissues and organs may represent the tar-
get of the autoimmune attacks, thus leading to a wide spectrum
of clinical features. As already mentioned, the three main compo-
nents of APECED are CMC, CH, and AD. CMC is, generally, the
first component to develop, often followed by CH, before the age
of 10 years and later by adrenal insufficiency (73, 74). In addition
to the main components, the spectrum of minor manifestations
may include ectodermal dystrophy, other endocrinopathies, such
as hypergonadotripic hypogonadism, insulin-dependent diabetes,
autoimmune thyroiditis, and pituitary dysfunction. Moreover,
gastrointestinal disorders (chronic atrophic gastritis, pernicious
anemia, malabsorption, autoimmune hepatitis and cholelithia-
sis), skin diseases (vitiligo and alopecia), keratoconjunctivitis,
immunological defects, asplenia may be present (70). More rare
manifestations of the disease include immune-mediated cen-
tral and peripheral neurological manifestations, such as chronic
inflammatory demyelinating polyneuropathy (54) and posterior
reversible encephalopathy syndrome (PRES) (75), tubulointersti-
tial nephritis, autoimmune bronchiolitis, reversible metaphyseal
dysplasia, hypokalemia, and hypertension (72).
The majority of APECED components have been correlated
with specific autoantibodies that may represent an useful tool for
the diagnosis and the follow-up of patients (Table 1). Autoan-
tibodies’ profile may parallel clinical expression even though a
strong correlation with the phenotype and the severity of the dis-
ease is not always present. Indeed, only some autoantibodies are
highly predictive of specific organ’s failure, being detectable years
before the onset of the overt clinical manifestations.
APCED-related CMC has been associated with the presence
of specific autoantibodies against the Th17-related cytokines
interleukin- (IL-) 22 and IL-17F (76, 77). A parathyroid-
specific autoantigen called NACHT leucine-rich-repeat protein 5
(NALP5), which is expressed in the cytoplasm of the main cell type
in the parathyroid glands (78), has been recently proposed as the
immunological hallmark of APECED-related CH.
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Table 1 | Clinical counter part of autoantibodies profile in APECED
[modified by Capalbo et al. (73)].
Clinical features Autoantibodies
CMC Abs against IL-22, IL-17F, and myosin-9
ENDOCRINE MANIFESTATIONS
HP Abs against NALP5
AD Abs against CYP21, CYP11A1, CYP17
Ovarian failure Ab against CYP11A1, CYP17, and NALP5
Type 1 diabetes Ab against IA-2 and insulin
Autoimmune thyroiditis Ab against TPO and Tg
NON-ENDOCRINE MANIFESTATIONS
Ectodermal manifestations
Vitiligo Abs against Melanocytes, SOX-9,
SOX-10, and AADC
Alopecia Abs against TH
Gastrointestinal manifestations
Autoimmune gastritis/
pernicious anemia
Abs against parietal cells and IF
Autoimmune hepatitis Abs against CYP-1A2, CYP-2A6, AADC,
and TPH
Autoimmune enteropathy Abs against TPH, HD, and GAD
Rare manifestations
Pulmonary disease Abs against KCNRG
Demyelinating polyneuropathy Abs against myelin protein zero
Tubular interstitial nephritis Abs against proximal tubule
Non-organ specific Abs Abs against IFN-α and IFN-ω
Abs, autoantibodies; IL-17F, interleukin 17F; IL-22, interleukin 22; NALP5,
NACHT leucine-rich-repeat protein 5; CYP21, 21-hydroxylase; CYP11A1, cho-
lesterol side-chain cleavage enzyme; CYP17, 17-α-hydroxylase; IA-2, tyrosine
phosphatase-like protein; TPO, thyroid peroxidase; Tg, thyroglobulin; AADC, aro-
matic l-amino acid decarboxylase; TH, tyrosine hydroxylase; IF, intrinsic factor;
TPH, tryptophan hydroxylase; HD, histidine decarboxylase; GAD, glutamic acid
decarboxylase; CYP-1A2, cytochrome P450 1A2; CYP-2A6, cytochrome P450
2A6; KCNRG, potassium channel-regulating protein; IFN-α, interferon α; IFN-ω,
interferon ω.
Antibodies against the enzyme 21-hydroxylase (CYP21) are
strongly associated and highly predictive for the development
of AD in patients with CH and/or CMC (79, 80). Steroido-
genic enzymes such as Cholesterol side-chain cleavage enzyme
(CYP11A1) and 17α-hydroxylase/17,20-lyase (CYP17) represent
a further targets of autoimmune reaction against adrenal cortex,
moreover they are highly correlated with ovarian insufficiency due
to lymphocytic oophoritis and can precede the clinical onset of the
component (81, 82). Autoimmune gastritis is associated with the
presence of autoantibodies against parietal cells and intrinsic fac-
tor (IF), the latter being involved in the development of pernicious
anemia (83). The presence of autoantibodies against tryptophan
hydroxylase (TPH), an enzyme involved in the synthesis of neu-
rotransmitters in the nervous system and in the gastrointestinal
endocrine cells correlates with Autoimmune enteropathy (84–87).
Moreover, autoantibodies against both histidine decarboxylase
(HD), an enzyme expressed in entero-chromaffin-like cells, and
GAD (88, 89) have been associated with an autoimmune intestinal
involvement. AH is mainly associated with the presence of autoan-
tibodies against cytochrome P4501A2 (CYP-1A2), CYP-2A6, and
aromatic l-amino acid decarboxylase (AADC), even though other
types of autoantibodies, such as those directed against TPH, have
been correlated with the AH component of the APECED pheno-
type (54, 90–92). Complement-fixing melanocyte autoantibodies
and antibodies against transcription factors SOX-9, SOX-10, and
AADC (83, 89) and tyrosine hydroxylase (TH) strongly corre-
late with the presence of vitiligo and alopecia (72, 83). Recently,
several reports have confirmed an important role of autoantibod-
ies against IFN-α and IFN-ω, which, although not tissue-specific,
have been detected in the serum of almost all APECED patients
(93, 94). Furthermore, they appear at a very early stage, often
before the onset of any clinical manifestation. With this regard,
their presence may be considered as an additional diagnostic
marker of the disease, especially in those cases with an atypi-
cal presentation (94, 95). Although autoantibodies’ production
seems to be a key-event in the development of the clinical dis-
ease, their role in the pathogenesis of APECED still remains to be
defined.
APECED is a paradigmatic example of an autoimmune mono-
genic disease, however, the phenotypic presentation can widely
vary from one patient to another (67, 70, 96, 97). Indeed, there
are observations documenting a genotype-phenotype correlation
only for specific traits (98, 99), but a clear genotype-phenotype
correlation is lacking. We have, recently, reported on a family
with an extremely wide intra-familial clinical variability despite
the same mutation of AIRE (100). These observations suggest
that genetic background is not able to explain alone the vari-
ability of the clinical expression and the severity of APECED
and that, as for other monogenic diseases, the phenotypic vari-
ability of the syndrome may result from the complex interaction
between several genetic, epigenetic, immunological, and/or envi-
ronmental factors. The HLA class I and class II alleles have been
reported to confer susceptibility to develop autoimmune diseases,
such as Type 1 diabetes and autoimmune thyroid diseases (101).
Only few studies investigated the association between the APECED
phenotype and HLA genotypes, reporting conflicting results. In
fact, although some studies did not find any significant asso-
ciation between HLA antigens class I or II and autoantibodies’
production or clinical expression of the disease (74, 102–104),
other showed an increased frequency of specific HLA genotypes
in APECED patients (105). However, in a more recent study
on 18 Sardinian patients (54) autoimmune hepatitis, as well as
LKM autoantibodies, have been found to be strongly associated
with HLA-DRB1*0301/DQB1*0201. However, there is no evi-
dence indicating that the HLA haplotype might be associated to
a particular severity of the disease. Infectious agents are potent
stimuli for the immune system, and thus both viruses and bacte-
ria can be considered as trigger of an autoreaction via different
mechanisms, such as molecular mimicry, bystander activation,
and epitope spreading (106–111). Moreover, evidence suggests
that a genetically determined susceptibility may favor the devel-
opment of an autoimmune disorder after an infection. Many
viruses have also been proposed as factors exacerbating several
autoimmune processes (112). However, the role of the infectious
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triggers has not been sufficiently investigated in patients with
APECED, and preliminary results did not show any significant
effect of different infections on the phenotypic expression of the
syndrome (100). As already mentioned, along with the central
tolerance network, which is primarily involved in the pathogen-
esis of APECED, several peripheral mechanisms are capable of
contributing to the control and regulation of the immune sys-
tem. These factors are involved in maintenance of the homeostasis
by controlling residual auto-reactive clones, which escape neg-
ative selection within the thymus and play a significant role in
preventing or minimizing reactivity to self-antigens. The periph-
eral tolerance recognizes as possible mechanisms the induction
of functional anergy with inactivation of self-reactive T-cells,
deletion of auto-reactive clones by apoptosis, through Fas/FasL
interaction, and the suppressive action of Tregs. An additional
mechanism involved in controlling reactivity to self engages in
the periphery is represented by NK cell activity. A possible role
of altered peripheral tolerance in the pathogenesis and clinical
expression of APECED might be hypothesized also considering
that recent evidence suggesting that Aire may also be implicated in
the control of peripheral mechanisms dedicated to the peripheral
maintenance of self-tolerance. In the periphery, Aire is expressed
in DCs and a specific population of extrathymic Aire-expressing
cells (113, 114). As in the thymus, also in secondary lymphoid
organs Aire is required for the expression of many TSAs. How-
ever, only few studies investigated the functionality of peripheral
tolerance mechanisms in patients with APECED and the role of
a failure in the peripheral mechanisms of Aire’s function is still
poorly defined. Studies on animal models of APECED suggest
that Aire does not influence per se Tregs as in Aire-KO mice
the number of CD4+CD25+ cells are normal, and the func-
tionality in in vitro suppression assays is normal as well (115,
116). However, the link between Aire and Treg cells is still not
fully understood. Some recent studies suggest that Aire-expressing
mTECs are involved in the generation of TSA-specific Foxp3+
Treg cells. A recent study supports this concept by showing that
Aire-expressing mTECs, in addition to providing an antigen reser-
voir, also serve as APCs, thus enhancing the selection of Treg
cells. The commitment of Tregs was shown to occur indepen-
dently of Foxp3, and interaction of developing thymocytes with
thymic stromal cells may drive the differentiation of a thymocyte
subpopulation into the Treg cell lineage and, subsequently, trig-
ger the expression of Foxp3 (117). Some adult APECED patients
have lower proportion of Tregs (118), this finding being probably
related to chronic infections, to the extent of autoimmune inflam-
mation or therapy. Unfortunately, Tregs have been evaluated in
only two children with APECED. Although in these children the
number of Tregs was reduced in comparison to healthy controls,
confirming the results obtained in adult patients, this reduc-
tion was not related to the severity of the disease, thus ruling
out a potential role in modulating the clinical expression of the
syndrome (100).
CLOSING REMARKS
Although APECED is a monogenic autoimmune disease, the great
variability of the clinical expression and the absence of a clear
genotype-phenotype correlation implies that, beyond AIRE muta-
tions, other susceptibility factors such as immunological and envi-
ronmental factors may be involved in the pathogenesis of the
disease. The evidence of a role of an impairment of central and
peripheral tolerance and of other susceptibility factors in the phe-
notypic variability of APECED is limited and needs to be further
investigated. So far, the reason of such variability still remains
obscure. Unraveling the open issues of the molecular basis of
APECED, will be extremely useful in improving the diagnosis,
management, and therapeutical strategies of this complex disease.
As for other Mendelian diseases, total exome sequencing could
be a good perspective to analyze other genetic variations and to
identify potential disease-modifying genes involved in the clinical
expressivity of organ-specific autoimmunity.
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